Navigation Links
Regeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day
Date:9/28/2010

TARRYTOWN, N.Y., Sept. 28 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Eye Diseases: Novel Therapies for Wet AMD, Retinal Vein Occlusion and Diabetic Macular Edema" at Citi's 5th Annual Biotech Day on Tuesday, October 5, 2010.  The panel discussion will be broadcast live at 8:00 a.m. Eastern Time and may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through November 4, 2010.  

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.Investor Relations914.345.7799michael.aberman@regeneron.comPeter DworkinCorporate Communications914.345.7800peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- In its first major ... company dedicated to advancing development of the ... release drug therapies in patient disease populations ... the acquisition of Enzon Pharmaceutical,s PEGylation Linker ... product pipeline. Acquisition of this technology will ...
(Date:6/19/2013)... , June 19, 2013 Pharma ... new infographic summary of the results from an ... third of all respondents stated that CROs would be an ... of respondents will be running 6 or more clinical trials ... the Clinical Trial Supply USA Summit ...
(Date:6/18/2013)... 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... today that VPII Escrow Corp., a newly formed wholly ... offer of approximately $3.2 billion aggregate principal amount of ... due in 2021 and in 2023, with final tranching ... use the net proceeds from the offering, together with ...
Breaking Medicine Technology:Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 2Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 3Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies 4Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... 24 Children,s Mental Focus,Foundation (CMFF), a nonprofit ... that may be linked to children with autism ... currently working with,doctors that have patients afflicted with ... adults cope with behavioral problems,associated with mental disorders ...
... Marketers, who have the,primary responsibility for communicating the ... as top challenges for pharmaceutical,companies when communicating trial ... worry about competitors stealing your,thunder, but also worry ... According to a Best Practices, LLC benchmarking study, ...
Cached Medicine Technology:Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 2Children's Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD 3Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies 2
(Date:6/19/2013)... Chicago is cracking down on bed bugs. New legislation ... require landlords to exterminate any and all reported bed bug ... also makes tenants responsible for reporting signs of bed bugs ... include disposing of furniture, bedding, and more. , In January ... more bed bug business in Chicago than any other city. ...
(Date:6/19/2013)... North American Seminars combines a live ... with an online continuing education course directed at ... , The two day live physical ... online continuing education course will provide the ... needed to evaluate and treat dizziness and imbalance. ...
(Date:6/19/2013)... A blow to the head; a swift jarring to ... to hours. It’s understandable, but what else may follow ... traumatic brain injury. According to mayoclinic.com , usual ... But many other symptoms may follow, sometimes not for ... include ongoing headaches, dizziness, feeling like you’re in a fog, ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The website ... describing insulin resistance, its harmful effects and tips to ... article and video from HealthNewsWires.com, the author defines ... ability to efficiently remove and process glucose from the ... source required by all cells, organs and systems of ...
(Date:6/19/2013)... 2013 Audibel Hearing Center is ... tinnitus patients, the A2 with Multiflex Tinnitus Technology. ... ringing in the ears. Although bothersome, tinnitus usually ... body. , Using their patent-pending Multiflex Tinnitus Technology, ... comforting sound stimulus that resonates through the patient’s ...
Breaking Medicine News(10 mins):Health News:Chicago Ordinance Requires Landlords and Tenants to Take Responsibility for Bed Bugs 2Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2Health News:Concussions Can Lead to Much More Than a Headache, According to MMTR Health Inc. Founder, Terry Moore, Neuromuscular and Cardiovascular Physiologist 2Health News:Effects of Insulin Resistance and How to Increase Insulin Sensitivity Published in New Video by Health News Wire 2Health News:Audibel Hearing Center Introduces A2 with Multiflex Tinnitus Technology 2
... efforts to cut back, , , SATURDAY, April 25 (HealthDay News) ... important lifestyle changes people with heart failure can make, but ... has found. , Researchers asked 116 people with heart ... Though the recommended daily intake of sodium for people with ...
... more potent treatment with fewer side effects , , SATURDAY, ... more direct delivery of cancer drugs to tumors have ... safe, biodegradable polymer, the nanoparticles are chemically engineered to ... most human tumors, and to carry a higher concentration ...
... - Plastic Surgery increased too, with breast implants and ... bank balances and stunning senior celebs are influencing factors.MANCHESTER, ... has been seen by staff at Transform, the UK,s ... Botox Grannies.More and more women over 60 are having ...
... Research , an association of technology analysts, market researchers, and science ... for expanding the pool of associates and tripling of publication schedule ... ... 2009 -- STIX Market Research , an association of technology ...
... a person,s insurance coverage affect their access to quality ... Center, insurance coverage may not only affect a patient,s ... care they receive. Research findings, presented today at the ... a national debate on healthcare reform. , "We ...
... Ill., April 24 World Veterinary Day, April 25, ... farmers. "This year,s theme, ,Veterinarians and Livestock ... partnership, highlights a discipline of veterinary medicine ... said Dr. W. Ron DeHaven, DVM, MBA, Chief Executive ...
Cached Medicine News:Health News:Hidden Salt in Diet Haunts Many With Heart Failure 2Health News:Nanoparticles May Help Attack Cancer More Directly 2Health News:Growth of Plastic Surgery & Botox Grannies in UK 2Health News:Growth of Plastic Surgery & Botox Grannies in UK 3Health News:STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase 2Health News:STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase 3Health News:STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase 4Health News:Does a person's insurance coverage affect their access to quality cancer care? 2Health News:AVMA Celebrates World Veterinary Day 2
The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum....
... over 30 years, Digisonics has set ... with the first review station, the ... and the best multi-modality reporting., ,DigiView ... image review workstations, professional reporting choices, ...
... Cortisol is a glucocorticoid produced by ... hormone (ACTH). It is secreted with a ... waking in the morning. Cortisol is often ... of hypertension, stress, AIDS, and in the ...
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
Medicine Products: